Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 8.125
Bid: 8.00
Ask: 8.25
Change: -0.50 (-5.80%)
Spread: 0.25 (3.125%)
Open: 8.625
High: 8.625
Low: 8.125
Prev. Close: 8.625
IXI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Correction to the Form of Proxy

15 Dec 2009 15:12

RNS Number : 1597E
Phytopharm PLC
15 December 2009
 

Correction to the Form of Proxy for Holders of Ordinary Shares, Form of Direction - Share Incentive Plan 2007 and Form of Direction to Exercise Voting Rights - General Meeting, each dated 3 December 2009

Phytopharm plc (the "Company")

In the summaries of the resolutions to be voted on at the general meeting of the Company at 11.00am on 29 December 2009 at the offices of KBC Peel Hunt Ltd, 111 Old Broad Street, London EC2N 1PH, it has been noted that in the Form of Proxy for Holders of Ordinary Shares, Form of Direction - Share Incentive Plan 2007 and Form of Direction to Exercise Voting Rights - General Meeting dated 3 December 2009 (the "Forms"), the summary of resolution 2 refers to shares being issued to an aggregate nominal value of £25,212,904.20 rather than £2,521,290.42; and the summary of resolution 4 refers to a subscription price of £0.01 rather than £0.10.  All other details in the Forms and all details in the notice of general meeting remain unchanged. 

The full text of each of these amended resolution summaries is set out below: "2.  To authorise the Directors for the purposes of section 551 of the Act to exercise all the powers of the Company to allot and grant rights to subscribe for or to convert securities into shares of the Company up to an aggregate nominal amount of £2,521,290.42 pursuant to or in connection with the Placing and Open Offer." "4. To approve the issue of Ordinary Shares pursuant to the Placing and Open Offer at a subscription price of £0.10 each (representing a discount of approximately 33.3 per cent. to the closing middle market price for an Ordinary Share for the business day immediately preceding the date on which the Company announced such price)."

For further information contact:

Phytopharm plc

Tel: +44 (0)1480 437 697

Sandy Morrison (Acting CEO)

Keith Thomson (Interim COO)

Alistair Taylor (Non-executive Chairman)

KBC Peel Hunt Ltd (Sponsor, Broker & Underwriter)

Tel: +44 (0)20 7418 8900

Capel Irwin / Matt Goode (Corporate Finance)

Marianne Woods / Dan Webster (Corporate Broking)

Notes:

Phytopharm is listed on the Official List of the London Stock Exchange. Further information on Phytopharm is available from the Company's website www.phytopharm.com.

KBC Peel Hunt Ltd, which is regulated by the FSA, is acting as Sponsor, Broker and Underwriter for the Company and is not acting for any other person and will not be responsible to any other person for providing the protections afforded to clients of KBC Peel Hunt Ltd or for providing advice in relation to the Placing and Open Offer, Admission or any other arrangements referred to herein.

This announcement has been issued by, and is the sole responsibility of, Phytopharm. Apart from the responsibilities and liabilities, if any, which may be imposed by FSMA, KBC Peel Hunt Ltd nor any of its affiliates, parent undertakings, subsidiary undertakings or subsidiaries of its parent undertakings or any of its respective directors, officers, employees or advisers or any other person accepts any responsibility whatsoever and makes no representation or warranty, express or implied, for or in respect of the contents of this announcement or as to the accuracy or completeness or fairness of the information or opinions contained in this announcement and, without prejudice to the generality of the foregoing, no responsibility or liability is accepted by any of them for any such information or opinions or for any errors or omissions. 

This announcement does not constitute an offer to sell or an invitation or solicitation to purchase or subscribe for any securities. The Placing and Open Offer will be made solely by the Prospectus which will contain the full terms and conditions of the Placing and Open Offer, including details of how the Placing and Open Offer may be accepted. Any acceptance or other response in relation to the Placing and Open Offer should be made only on the basis of the information contained in the Prospectus.

Any New Ordinary Shares issued or to be issued pursuant to the Prospectus have not been and will not be registered under the US Securities Act, or any relevant securities laws of any state of the United States. Subject to certain exceptions, such New Ordinary Shares may not be offered, sold or delivered in the United States or to or for the account or benefit of U.S. persons, as such terms are defined in Regulation S under the US Securities Act.

Definitions:

The following definitions apply throughout this announcement, unless the context requires otherwise:

"Admission"
the admission of the New Ordinary Shares (i) to the Official List and (ii) to trading on the London Stock Exchange's main market for listed securities becoming effective in accordance with, respectively LR 3.2.7G of the Listing Rules and paragraph 2.1 of the Admission and Disclosure Standards
 
 
"Admission and Disclosure Standards"
the requirements contained in the publication dated 7 September 2009
 
 
"Existing Ordinary Shares"
the 94,548,381 existing ordinary shares of 1 pence each in nominal value in the capital of the Company as at 3 December 2009
 
 
"Financial Services Authority"or "FSA"
the UK Financial Services Authority
 
 
"FSMA"
the Financial Services and Markets Act 2000 (as amended) and all regulations promulgated thereunder from time to time
 
 
"Listing Rules"
the listing rules made by the FSA in exercise of its function as competent authority pursuant to Part VI of FSMA
 
 
"London Stock Exchange"
London Stock Exchange plc
 
 
"New Ordinary Shares"
the 252,129,042 new Ordinary Shares of 1p each in nominal value in the capital of the Company proposed to be issued under the Placing and Open Offer
 
 
"Official List"
the Official List of the FSA
 
 
"Open Offer"
the conditional invitation to Qualifying Shareholders to apply for up to 252,129,042 New Ordinary Shares at the Offer Price on a pre-emptive basis
 
 
"Ordinary Share"
ordinary shares in the capital of the Company from time to time
 
 
"Overseas Shareholders"
Qualifying Shareholders who have registered addresses outside the United Kingdom
 
 
"Placing"
the conditional placing by KBC Peel Hunt of 172,090,285 New Ordinary Shares, subject to clawback pursuant to the Open Offer, on behalf of the Company on the terms and subject to the conditions contained in the Placing Agreement
 
 
"Placing Agreement"
the placing and open offer agreement dated 3 December 2009 between KBC Peel Hunt and the Company relating to the Placing and Open Offer
 
 
"Prospectus"
the prospectus in relation to the Placing and Open Offer dated 3 December 2009
 
 
"Qualifying Shareholders"
holders of Existing Ordinary Shares on the register of members of the Company on the Record Date (other than certain Overseas Shareholders)
 
 
"Record Date"
30 November 2009
 
 
"Shareholder"
a holder of Existing Ordinary Shares(s)
 
 
"US", "USA" or "United States"
 the United States of America, its territories and possessions, any state of the United States of America and the District of Columbia
 
 
"US Securities Act"
the United States Securities Act of 1933, as amended

All references to "pounds", "pounds sterling", "Sterling", "£", "pence", "penny" and "p" are to the lawful currency of the United Kingdom.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEELFFKLBBFBX
Date   Source Headline
15th Apr 20247:00 amRNSLife Molecular Imaging – Neuraceq Supply Agreement
3rd Apr 20247:00 amRNSImeka Collaboration Agreement
13th Mar 20247:00 amRNSTrading Update
29th Jan 202412:00 pmRNSHolding(s) in Company
25th Jan 20244:00 pmRNSResult of AGM
12th Jan 20249:35 amRNSDirectorate Change
27th Dec 20237:00 amRNSUpdate regarding Nominated Adviser and Broker
15th Dec 20237:00 amRNSChange of Auditor
5th Dec 20237:00 amRNSFinancial Results for year ended 30 September 2023
27th Nov 20237:00 amRNSNotice of Results and Investor Presentation
5th Oct 20237:00 amRNSAppointment of Independent Non-Executive Director
29th Sep 20237:00 amRNSTrading Update
18th Jul 20237:00 amRNSContract Win
14th Jun 20237:00 amRNSContract Win
23rd May 20237:00 amRNSHalf year report
16th May 20237:00 amRNSInvestor Meet Company presentation
10th May 20237:00 amRNSTrading Update
3rd Apr 20238:35 amRNSExtension of Huntington's disease consortium
21st Mar 202312:11 pmRNSHolding(s) in Company
10th Mar 20237:00 amRNSContract Win
7th Feb 20237:00 amRNSTrading Update
31st Jan 20234:35 pmRNSPrice Monitoring Extension
31st Jan 20232:05 pmRNSSecond Price Monitoring Extn
31st Jan 20232:00 pmRNSPrice Monitoring Extension
31st Jan 202311:05 amRNSSecond Price Monitoring Extn
31st Jan 202311:00 amRNSPrice Monitoring Extension
27th Jan 20231:00 pmRNSResult of AGM
3rd Jan 20237:00 amRNSTotal Voting Rights
22nd Dec 202212:18 pmRNSDirector Bed & ISA Dealing
13th Dec 20227:00 amRNSPDMR Exercise of Options
9th Dec 20229:05 amRNSContract Win
8th Dec 20223:34 pmRNSContract Update
7th Dec 20227:00 amRNSFinancial Results for the year ended 30 Sept 2022
21st Nov 20227:00 amRNSNotice of Results and Investor Presentation
25th Oct 20227:00 amRNSTrading Update
21st Sep 202210:35 amRNSHD-IH Consortium
14th Sep 20227:00 amRNSGrant of Share Options
1st Sep 20227:00 amRNSTrading Update and FY2023 Guidance
4th Aug 20227:00 amRNSContract Win
26th Jul 202211:22 amRNSContract Win - Replacement
21st Jul 20227:00 amRNSContract Win
14th Jun 20227:00 amRNSContract Extension
24th May 20227:00 amRNSHalf-year Report and Trading Update
16th May 20227:00 amRNSInvestor Presentation
10th May 20227:00 amRNSConsortium Agreement in Huntington's Disease
25th Apr 20227:00 amRNSTrading Update
21st Apr 20227:00 amRNSNew Contract Win
8th Mar 20227:00 amRNSContract worth circa £800k
14th Feb 20227:00 amRNSLaunch of IXIQ.Ai Deep learning AI-based platform
8th Feb 202212:30 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.